A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S.
Amoury M, et al. Among authors: pardo a.
Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15.
Int J Cancer. 2016.
PMID: 27037627